Skip to content

Bausch + Lomb Corp

🇺🇸XNYS.BLCOUnited StatesHealthcare

$16.86USDup +0.04 (+0.24%)ClosedDelayed3:55 AM

Price$16.86+0.04 (+0.24%)

Latest anomalies

Neutral 0 detected in the last 120 days

  • High: 0
  • Medium: 1
  • Low: 0
  • Gross profit margin: a sudden drop below its trailing quarter average

    Fundamentals Medium

View all anomalies

Free with a Finzer account.

Profile

  • Healthcare
  • Medical Instruments & Supplies
  • United States

Identity

Type
Stock
ISIN
CA0717051076
CUSIP
Not reported

Company

Employees
13,500
Headquarters
Vaughan, United States

Market

Shares outstanding
357.2M
Market cap
$5.99B

Key dates

Next earnings
Nov 4, 2026

Highlights

Day range$16.83 - $16.97
today's session
52-week range$13.77 - $18.87
from 250 sessions
Market cap
$6.05B
EPS LTM
-$0.77
P/E LTM
-27.04
Div yield
Not reported

Fundamentals (LTM)

Revenue
$4.89B+8.81%up year on year
Net income
-$273M+40.13%up year on year
Gross margin
59.68%-1.91%down year on year
Free cash flow
-$165M-23.13%down year on year

View all financials

Latest news

Sentiment . 90dwidened from 7d

  • 14%Positive
  • 29%Neutral
  • 57%Negative
7 articles from 2 sources

View all news

Business summary

Bausch + Lomb Corp is a company in the healthcare sector, listed on New York Stock Exchange (United States) under the ticker BLCO. Its market capitalisation is $5.99B, from 357.2M shares outstanding, as of . Across the 250 trading sessions to the shares traded between $13.77 and $18.87, and the last close of $16.86 sits 61% of the way up that range. The company is headquartered in Vaughan, United States, and employs about 13,500 people. This is the New York Stock Exchange listing of Bausch + Lomb Corp; its primary listing is BLCO on Toronto Stock Exchange.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.